An observational study in Obesity, Obesity With Complications and Weaning From Mechanical Ventilation in Care Unit, sponsored by Assistance Publique - Hôpitaux de Paris. Recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-06-05.
Sponsored by Assistance Publique - Hôpitaux de Paris · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 58 studies in Obesity by Assistance Publique - Hôpitaux de Paris — 16 open to participants now, 16 under way, 1 of them phase 3. Obesity · Assistance Publique - Hôpitaux de Paris.
Among the 58 studies in Obesity by Assistance Publique - Hôpitaux de Paris, this one is the 17th largest by planned enrollment of the 20 observational ones that give a count, is one of 6 that started in 2025, is one of 20 observational ones, reaches primary completion later than 5 of the 15 other live ones, and was the 53rd registered.
11,564 studies on the registry are indexed under Obesity; 2,063 are open to participants now.
Browse Obesity studies →16 of the 58 studies in Obesity by Assistance Publique - Hôpitaux de Paris are open now, in 1 country. Recruiting first, the newest first:
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18–85
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18–64 · Women only · Healthy volunteers
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18+
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 12+
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18–65
By country, each count listing its studies:
Of the 1,352 Obesity studies recruiting now, 382 (28%) set no upper age limit and 867 (64%) stop at 75 or younger; 169 take children under 18; 491 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
58 studies; the count open now beside each. This study's row is marked.
First in 2002; this study’s year is marked. 6 started in 2025.
This study's planned enrollment of 80 is below the median of 115 across 2,159 observational studies indexed under Obesity.
Median enrollment 110 across the 38 interventional studies, 175 across the 20 observational. Of the 36 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Assistance Publique - Hôpitaux de Paris is the lead sponsor of 3,598 studies on the registry; 1,038 are open to participants now.
4 of the studies in Obesity by Assistance Publique - Hôpitaux de Paris that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06867354Assistance Publique - Hôpitaux de ParisPrevalence, Determinants and Consequences of Dyspnea During Weaning in Critically Ill Obese Patients | 2027-03 |
| NCT06380426Assistance Publique - Hôpitaux de ParisA Multicenter Pharmacoepidemiological Cohort on Real Life Use of Semaglutide in Adolescents or Adults With Monogenic Obesity | 2027-04-30 |
| NCT04893954Assistance Publique - Hôpitaux de ParisProspective Study on the Consequences of Weight Loss After Bariatric Surgery on Obese Patients' Spine. | 2027-07 |
| NCT06899997Assistance Publique - Hôpitaux de ParisStudy of the Effects of Time-Restricted Feeding on the Immune Function of Individuals With Obesity | 2027-09-15 |
Add all 4 to your calendar (.ics) → With an account.
Among the 58 studies in Obesity by Assistance Publique - Hôpitaux de Paris, from their registry updates:
This tab as a report to print or save as PDF → With an account.
ICU patients encounter numerous discomforts, with dyspnea (the sensation of breathlessness) being among the most distressing and impactful. Unlike pain, dyspnea in ICU settings has historically received limited attention, despite its severe psychological impact. ICU clinicians often use assessment tools like the simple numerical dyspnea scale (Dyspnea-VAS) and the Respiratory Distress Observation Scale (MV-RDOS) to measure dyspnea. These scales are also utilized during the weaning process, an essential phase when patients attempt to breathe independently without ventilator assistance. Weaning is crucial for ICU patients, as delayed or unsuccessful extubation increases the risk of complications and mortality.
Obese ICU patients, often admitted due to respiratory failure, present unique challenges due to physiological changes in the respiratory system, such as reduced functional residual capacity and decreased lung compliance. These factors contribute to an increased likelihood of dyspnea and weaning complications. Approximately 50% of obese ICU patients require mechanical ventilation, and once ventilated, obese patients exhibit an elevated risk for dyspnea and ventilator weaning failure.
Understanding the prevalence, causes, and consequences of dyspnea and failure in weaning process in obese ICU patients is critical. In this study, the aim is to compare obese patients with non-obese patients in terms of dyspnea prevalence, causes and consequences as weaning failure prevalence, causes and consequences.
Research Justification:
ICU patients face numerous sources of discomfort, among which dyspnea- the subjective sensation of breathlessness-stands out as especially distressing. Unlike pain, dyspnea has historically received limited attention, despite its severe psychological impact, including feelings of panic and death anxiety. Dyspnea integrates both physical and psychological suffering, often leading patients to report it as one of the most unbearable experiences, highlighting its significance for ICU caregivers. The subjective nature of dyspnea presents a diagnostic challenge, as it may occur without visible respiratory distress, which complicates detection and management. Dyspnea arises from complex mechanisms, including increased respiratory muscle load from airway resistance or thoracic compliance reduction. Additionally, dyspnea can be induced by an increased need for air due to elevated carbon dioxide levels or reduced oxygen levels, triggering chemoreceptor responses.
For ICU patients mechanically ventilated, the prevalence of dyspnea has been reported between 34 and 47%. Dyspnea assessment tools, such as the Dyspnea-VAS (Visual Analog Scale) and the MV-RDOS (Respiratory Distress Observation Scale), are employed to measure dyspnea, even in intubated patients. These tools are especially useful during ventilator weaning, a critical phase when patients transition to spontaneous breathing. The weaning process, and particularly the spontaneous breathing test (SBT), a test during which the patient breath with the assistance of the ventilator, is critical. The failure of a SBT can increase mortality risk, length of mechanical ventilation and ICU stay.
In this study, the investigators focus in obesity. The growing prevalence of obesity adds an additional layer of complexity to ICU care, as obese patients present distinct challenges during ventilation and weaning. With physiological changes such as reduced lung compliance and increased airway resistance, obese patients have an elevated risk for dyspnea and ventilator weaning complications. Obesity prevalence surged during the COVID-19 pandemic until 40% of ICU patients, and today, up to 50% of obese ICU patients require mechanical ventilation.
In ICU obese patients and mechanically ventilated, there is no assessment of dyspnea, its determinants and its impact during ventilatory weaning. The pathophysiology of dyspnea and SBT failure is complex and primarily involves cardiac function and respiratory muscle function. Pulmonary edema is found in more than half of cases and is linked to the transition from a positive pressure ventilation regime to a negative pressure regime, which creates unfavorable loading conditions for the heart. The second cause described is diaphragmatic dysfunction characterized by atrophy of the respiratory muscles which can occur rapidly under mechanical ventilation. More recently, dyspnea has been described as a cause of SBT and extubation failure in its own right. Other causes have also been described such as intensive care neuropathy, iatrogenic causes (agitation, pain), anxiety, or even impaired ventilatory control.
In addition, the consequences of dyspnea and failure of SBT as well as their management are not described, such as the duration of mechanical ventilation, mortality, length of stay, intercurrent events such as new sepsis. or the administration of new treatments during the period from weaning to extubation.
Finally, the evolution of dyspnea after successful SBT and after extubation has never been described.
The prevalence, determinants and consequences of dyspnea and failure of the first SBT as well as their management in ICU patients with obesity have never been described. Likewise, improving the diagnostic performance of the clinical criteria for SBT failure with the contribution of dyspnea scales is a real challenge in these patients.
Research Design and Methodology:
Study Type: This is a descriptive, monocentric and comparative study.
Patients hospitalized in intensive care under mechanical ventilation for at least 48 hours, with or without obesity (BMI > 30 kg/m²).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Presence or onset of dyspnea
Presence or onset of dyspnea detected by the simple numerical dyspnea scale (Dyspnea-Visual Analog Scale VAS) from 0 to 10 cm , 0 means "no respiratory discomfort, no sensation of shortness of breath, no difficulty breathing" and 10 means "the worst imaginable respiratory discomfort, feeling of shortness of breath, inability to breathe" ≥ 4 before, and then at 2 minutes, 15 minutes, 30 minutes, and at the end of SBT. In order to describe the prevalence of dyspnea during the first SBT in obese patients hospitalized in the ICU compared to non-obese patients.
Time frame: Baseline
Measure of the affective component of dyspnea using the simple numerical dyspnea scale
Measure of the affective component of dyspnea using the simple numerical dyspnea scale (Dyspnea-Visual Analog Scale VAS) from 0 to 10, 0 means "no anxiety related to dyspnea" and10 means "maximum anxiety related to dyspnea" before, and then at 2 minutes, 15 minutes, 30 minutes, and at the end of SBT, anxiety if Dyspnea-VAS \> 4, in order to describe the prevalence of dyspnea during the first SBT in obese patients hospitalized in the ICU compared to non-obese patients.
Time frame: Baseline
: Presence or onset of dyspnea detected by the Mechanical Ventilation - Respiratory Distress Observation Scale
Presence or onset of dyspnea detected by the Mechanical Ventilation - Respiratory Distress Observation Scale (MV-RDOS) in mechanically ventilated in non-communicating patients from 0 to 5, 0 means no dyspnea and 5 means major dyspnea, before SBT then at 2 minutes, 15 minutes, 30 minutes, and at the end of SBT, dyspnea if MV-RDOS\> 2.6, in order to describe the prevalence of dyspnea during the first SBT in obese patients hospitalized in the ICU compared to non-obese patients.
Time frame: Baseline
Measure of Rapid Shallow Breathing Index (RSBI) (the ratio of respiratory frequency (f) to tidal volume (TV)) measured at 1 minute of SBT > 105 breaths/min/L.
Measure of Rapid Shallow Breathing Index (RSBI) in order to describe the prevalence of dyspnea during the first SBT in obese patients hospitalized in the ICU compared to non-obese patients.
Time frame: Baseline
Measure of Pain with Visual Analog Scale (VAS) for pain from 1 to 100 mm (1 means no pain, 100 means major pain)
Measure of pain in order to describe the main determinants of dyspnea during the first SBT in ICU patients and affected (case) or not (control) by obesity
Time frame: Baseline
Research of anxiety with Hospital Anxiety and Depression Scale (HADS) from 0 to 21, 0 means no anxiety, 21 means major anxiety, anxiety if HADS > 8
Research of anxiety in order to describe the main determinants of dyspnea during the first SBT in ICU patients and affected (case) or not (control) by obesity
Time frame: Baseline
Number of patients with Respiratory Control Impairment:
Number of patients with Respiratory Control Impairment in order to describe the main determinants of dyspnea during the first SBT in ICU patients and affected (case) or not (control) by obesity
Time frame: Baseline
Measure of the number of treatments added during SBT
Measure of the number of treatments added during SBT in order to describe the main determinants of dyspnea during the first SBT in ICU patients and affected (case) or not (control) by obesity
Time frame: Baseline
Measure of the number of patients with early cessation of SBT at the patient's request for reasons unrelated to the validated clinical objective criteria for SBT failure;
Measure of the number of patients with early cessation of SBT at the patient's request in order to describe the clinical and therapeutic consequences of dyspnea between the first SBT and extubation in ICU patients and affected (case) or not (control) by obesity.
Time frame: Length of the ICU hospitalization (2 months maximum)
Measure of number of SBT performed until extubation
Measure of number of SBT performed until extubation in order to describe the clinical and therapeutic consequences of dyspnea between the first SBT and extubation in ICU patients and affected (case) or not (control) by obesity.
Time frame: Length of the ICU hospitalization (2 months maximum)
Measure of the duration between the first SBT and the extubation
Measure of the duration between the first SBT and the extubation in order to describe the clinical and therapeutic consequences of dyspnea between the first SBT and extubation in ICU patients and affected (case) or not (control) by obesity.
Time frame: Length of the ICU hospitalization (2 months maximum)
Measure of the number of extubation failure defined by reintubation or death
Measure of the number of extubation failure in order to describe the clinical and therapeutic consequences of dyspnea between the first SBT and extubation in ICU patients and affected (case) or not (control) by obesity.
Time frame: Within 7 days following extubation;
Measure of the duration of invasive and non-invasive mechanical ventilation
Measure of the duration of invasive and non-invasive mechanical ventilation in order to describe the clinical and therapeutic consequences of dyspnea between the first SBT and extubation in ICU patients and affected (case) or not (control) by obesity.
Time frame: Length of the ICU hospitalization (2 months maximum)
Measure of the length of stay in the ICU
Measure of the length of stay in the ICU in order to describe the clinical and therapeutic consequences of dyspnea between the first SBT and extubation in ICU patients and affected (case) or not (control) by obesity.
Time frame: Length of the ICU hospitalization (2 months maximum)
Measure of number of deaths in ICU
Measure of number of deaths in ICU in order to describe the clinical and therapeutic consequences of dyspnea between the first SBT and extubation in ICU patients and affected (case) or not (control) by obesity.
Time frame: Length of the ICU hospitalization (2 months maximum)
Measure of number of intercurrent events between the clinical outcome of the first SBT and extubation
Measure of number of intercurrent events between the clinical outcome of the first SBT and extubation in order to describe the clinical and therapeutic consequences of dyspnea between the first SBT and extubation in ICU patients and affected (case) or not (control) by obesity.
Time frame: Length of the ICU hospitalization (2 months maximum)
Research of the number of treatments administered between the first SBT and extubation
Research of the number of treatments administered between the first SBT and extubation in order to describe the clinical and therapeutic consequences of dyspnea between the first SBT and extubation in ICU patients and affected (case) or not (control) by obesity.
Time frame: Length of the ICU hospitalization (2 months maximum)
Description of the prevalence of first SBT failure in ICU patients and affected (case) or not (control) by obesity.
SBT failure defined by the appearance of at least one of the following objective criteria 1. Respiratory rate ≥ 35 breaths/min or an increase ≥ 50% compared to the baseline value, 2. SpO2 ≤ 90% or PaO2 ≤ 50 mmHg with FiO2 ≥ 50%, 3. PaCO2 \> 50 mmHg, 4. Heart rate ≥ 140 beats per minute, 5. New supraventricular or ventricular arrhythmia, 6. Systolic blood pressure \>180 or \< 90 mmHg, 7. Altered consciousness, 8. Signs of respiratory distress.
Time frame: Baseline
Measure of the number of patient with pulmonary edema during weaning
Measure of the number of patient with pulmonary edema during weaning in order to describe the main causes of first SBT failure.
Time frame: Baseline
Measure of the number of patient with acute myocardial ischemia (coronary syndrome with or without ST-segment elevation)
Measure of the number of patient with acute myocardial ischemia (coronary syndrome with or without ST-segment elevation):in order to describe the main causes of first SBT failure.
Time frame: Baseline
Measure of the number of patient with respiratory muscle impairment and diaphragmatic dysfunction
Measure of the number of patient with respiratory muscle impairment and diaphragmatic dysfunction in order to describe the main causes of first SBT failure.
Time frame: Baseline
Measure of the number of patient with critical illness neuromyopathy
Measure of the number of patient with critical illness neuromyopathy in order to describe the main causes of first SBT failure.
Time frame: Baseline
Measure of the number of patient with dyspnea
Measure of the number of patient with dyspnea in order to describe the main causes of first SBT failure.
Time frame: Baseline
Measure of the number of patient with anxiety with Hospital Anxiety and Depression Scale (HADS) from 0 to 21, 0 means no anxiety, 21 means major anxiety, anxiety if HADS > 8
Measure of the number of Measure of the number of patient with anxiety in order to describe the main causes of first SBT failure.
Time frame: Baseline
Measure of the number of patient with respiratory control impairment:
Measure of the number of patient with respiratory control impairment in order to describe the main causes of first SBT failure.
Time frame: Baseline
Measure of the number of patient with an early cessation of the SBT at the patient's request, outside of the validated clinical objective criteria for SBT
Measure of the number of patient with an early cessation of the SBT at the patient's request, outside of the validated clinical objective criteria for SBT failure in order to describe the clinical and therapeutic consequences of the failure of the first SBT until extubation
Time frame: Length of the ICU hospitalization (2 months maximum)
Measure of Number of SBT performed until extubation
Measure of the number of Number of SBT performed until extubation in order to describe the clinical and therapeutic consequences of the failure of the first SBT until extubation
Time frame: Length of the ICU hospitalization (2 months maximum)
Measure of the Delay between the date of the first SBT and the date of extubation
Measure of the delay between the date of the first SBT and the date of extubation in order to describe the clinical and therapeutic consequences of the failure of the first SBT until extubation
Time frame: Length of the ICU hospitalization (2 months maximum)
Measure of the number of patient with an extubation failure defined by reintubation or death
Measure of the number of patient with an extubation failure defined by reintubation or death within 7 days following extubation in order to describe the clinical and therapeutic consequences of the failure of the first SBT until extubation
Time frame: Length of the ICU hospitalization (2 months maximum)
Measure of the duration of invasive and non-invasive mechanical ventilation
Measure of the duration of invasive and non-invasive mechanical ventilation in order to describe the clinical and therapeutic consequences of the failure of the first SBT until extubation
Time frame: Length of the ICU hospitalization (2 months maximum)
Measure of Duration of stay in the ICU
Measure of Duration of stay in the ICU in order to describe the clinical and therapeutic consequences of the failure of the first SBT until extubation
Time frame: Length of the ICU hospitalization (2 months maximum)
Measure of the number of deaths in the ICU
Measure of the number of deaths in the ICU in order to describe the clinical and therapeutic consequences of the failure of the first SBT until extubation
Time frame: Length of the ICU hospitalization (2 months maximum)
Measure of the number of Intercurrent events between the clinical outcome of the first SBT and extubation
Measure of the number of Intercurrent events between the clinical outcome of the first SBT and extubation in order to describe the clinical and therapeutic consequences of the failure of the first SBT until extubation
Time frame: Length of the ICU hospitalization (2 months maximum)
Evaluate the contribution of combining the dyspnea scales measured during SBT with the usual clinical criteria to predict the diagnosis of SBT failure.
Contribution of combining the dyspnea scales measured during SBT with the usual clinical criteria to predict the diagnosis of SBT failure (area under the curve, sensitivity, specificity, likelihood ratio).
Time frame: Length of the ICU hospitalization (2 months maximum)
Description of the evolution of dyspnea after extubation.
Simple numeric rating scale for dyspnea (Dyspnea- Visual Analogic Scale (VAS)) and simple numeric rating scale assessing relief of dyspnea from 0 to 10 cm, 0 means 'no relief, no impression of improvement in breathlessness' and 10 means 'extraordinarily relieved,' performed 60 minutes after extubation and at 24 hours, dyspnea if Dyspnea-VAS \> 4
Time frame: Length of the ICU hospitalization (2 months maximum)
Plan to share: Undecided
No publications or documents are linked to this record.
Started Mar 2025 (actual). Primary completion is estimated for Mar 2027, 24 months after the start.
Of 796 non-industry observational studies under Obesity, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 106. This study's planned 24 months is below that.
Counting every sponsor, half of 842 studies reached it within 39 months; a quarter within 17 and three quarters within 96.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Assistance Publique - Hôpitaux de Paris →